Hikma Pharmaceuticals (LON:HIK) Given “Buy” Rating at Jefferies Financial Group

Hikma Pharmaceuticals (LON:HIK)‘s stock had its “buy” rating restated by equities researchers at Jefferies Financial Group in a note issued to investors on Friday, Digital Look reports. They presently have a GBX 2,025 price objective on the stock. Jefferies Financial Group’s price objective suggests a potential upside of 26.56% from the stock’s previous close.

Several other equities analysts have also issued reports on the stock. Berenberg Bank lifted their price target on shares of Hikma Pharmaceuticals from GBX 1,800 to GBX 2,100 and gave the stock a “buy” rating in a report on Tuesday, August 11th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a GBX 1,950 price objective on shares of Hikma Pharmaceuticals in a research report on Friday, August 7th. Finally, Citigroup boosted their target price on Hikma Pharmaceuticals from GBX 1,700 to GBX 1,870 and gave the stock a “buy” rating in a research note on Wednesday, August 12th. Six equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of GBX 2,085.83.

Hikma Pharmaceuticals Stock Up 0.6%

Shares of LON HIK opened at GBX 1,600 on Friday. Hikma Pharmaceuticals has a 12-month low of GBX 1,187 and a 12-month high of GBX 1,865. The stock’s fifty day simple moving average is GBX 1,602.90 and its two-hundred day simple moving average is GBX 1,478.29. The stock has a market capitalization of £3.31 billion, a PE ratio of 9.09, a price-to-earnings-growth ratio of 2.38 and a beta of 0.66. The company has a current ratio of 1.98, a quick ratio of 1.27 and a debt-to-equity ratio of 77.57.

Insiders Place Their Bets

In related news, insider Tobias Hestler purchased 7,500 shares of the business’s stock in a transaction on Monday, August 10th. The shares were bought at an average cost of GBX 1,648 per share, with a total value of £123,600. Corporate insiders own 22.26% of the company’s stock.

About Hikma Pharmaceuticals

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.